Regenerative Medicines: Bone and Joint Applications

NEW YORK, July 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Regenerative Medicines: Bone and Joint Applications http://www.reportlinker.com/p0157460/Regenerative-Medicines-Bone-and-Joint-Applications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

INTRODUCTION

Regenerative medicine in orthopedic applications is a $2.7 billion per year niche sector in America's $2.6 trillion per year healthcare system. However, it is a sector of immense interest in terms of technical and medical possibilities. The best analogy to the current state of regenerative therapies in the bone and joint healing sector is the nascency of the microprocessors business back in 1971. At that time, microprocessors (namely Intel's 4004), and related innovations, were just an infinitesimal segment of electronic component sales, but this innovation came to dominate the economy. The regenerative therapies sector, particularly areas such as cell therapy and stem cell derived products is in a comparable position today.

The regenerative medicine industry has been in existence for nearly 25 years. Actual product sales, along with research and development (R&D) expenditures, are projected to amount to approximately $2.7 billion in economic activity in 2013, of which venture capital and R&D funding accounts for about $145 million. The rapid evolution of this business is evidenced by the industry consolidation that has occurred since the first edition of this BCC Research report was published in 2003 and even since the most recent edition in 2009. Innumerable buyouts, consolidations, product abandonments, new firms and a few bankruptcies, too, have occurred in just the last several years. These changes are reflected in the Company Profiles section of this report. In addition, intensive R&D efforts at universities, the National Institutes of Health, the National Science Foundation and at FDA centers that focus on cuttingedge technology underscore the importance of this industry.

Regenerative therapies have the potential to improve medical outcomes, enhance quality of life, and reduce overall healthcare costs. A key objective is the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process. The most successful products have drawn upon multidisciplinary fields such as biology, medicine, engineering, and, particularly, biomedical engineering.

The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important and are briefly covered to underscore the larger importance of regenerative therapies. Stemcell research is an important component of the sector as well. For example, the successful differentiation of embryonic stem cells into specific cell types is widely sought as a means to treat traumatic spinalcord injury, as well as diseases such as diabetes, Duchenne muscular dystrophy, heart disease, and vision and hearing loss.

OBJECTIVES AND GOALS OF STUDY

This report focuses on the bone and jointrelated applications of and markets for the various categories of regenerative medicine products currently available and projected to be introduced during the fiveyear forecast period from 2013 through 2018. Market drivers discussed include the status of R&D and what is likely to issue from R&D in the way of actual products and therapies. Other market drivers include the incidence, and rate of growth, of diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone and cartilagegrowthstimulating agents in a regenerative appliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

Profiles are provided of leading and emerging companies in the bone and joint regenerative medicine markets, along with analyses of the current and future positioning of their products and businesses in this active and rapidly changing market. Developmental and clinical stage companies are well covered.

Go here to read the rest:
Regenerative Medicines: Bone and Joint Applications